Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology

Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology

Authors

  • Maria Vadalà Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Modena, Italy,
  • Carmen Laurino Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Modena, Italy
  • Lucia Palmieri Department of Nephrology, University of Modena and Reggio Emilia Medical School, Modena, Italy.
  • Beniamino Palmieri Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy

Keywords:

alkylglycerols, shark liver oil, squalene, shark cartilage, urea, anti-squalene antibodies, cancer, lipids, anti-tumoral activity, oncology

Abstract

The capability of sharks to resist infection and the low incidence of tumors found in different species of sharks (e.g. spiny dogfish shark, tiger shark) suggested the presence into their tissues of active compounds, provided of anticancer activities, such as Alkylglycerols (from the shark liver), Squalene (from the shark mesenchyme and skin), and Cartilage (from the shark skeleton). The Alkylglycerols, highly concentrated in the shark liver oil, have several biological activities: stimulation of hematopoiesis, immune-modulation, anti-tumors. The Squalene is an anticancer, antioxidant, detoxifier, skin hydrating, drug carrier and emollient agent. The Cartilage has anti-inflammatory properties commonly used in the folk medicine for the treatment of arthritis, osteoarthritis, diabetic retinopathy, psoriasis, and supposedly also anticancer.

Downloads

Published

2017-06-08

Issue

European Journal of Oncology Vol.22, No.1 (2017)

Section

Reviews

License

OPEN ACCESS

All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.

The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).

Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.

How to Cite

1.
Vadalà M, Laurino C, Palmieri L, Palmieri B. Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology. Eur J Oncol Env Hea [Internet]. 2017 Jun. 8 [cited 2025 Apr. 10];22(1):5-20. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/5215